Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.

Bioorganic & medicinal chemistry letters·2016
Same author

Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent.

ACS medicinal chemistry letters·2016
Same author

Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.

Bioorganic & medicinal chemistry letters·2016
Same author

Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.

Current topics in medicinal chemistry·2015
Same author

The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.

Journal of medicinal chemistry·2015
Same author

The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.

Journal of medicinal chemistry·2015

Related Experiment Video

Updated: May 23, 2026

Chemical Modification of the Tryptophan Residue in a Recombinant Ca2+-ATPase N-domain for Studying Tryptophan-ANS FRET
12:07

Chemical Modification of the Tryptophan Residue in a Recombinant Ca2+-ATPase N-domain for Studying Tryptophan-ANS FRET

Published on: October 9, 2021

Dimerization of β-tryptase inhibitors, does it work for both basic and neutral P1 groups?

Guyan Liang1, Yong Mi Choi-Sledeski, Xin Chen

  • 1Molecular Innovative Therapeutics, Sanofi Pharmaceuticals, United States. guyan.liang@verizon.net

Bioorganic & Medicinal Chemistry Letters
|April 10, 2012
PubMed
Summary

Researchers explored dimeric inhibitors for beta-tryptase, aiming for novel drug development. Their attempt to create neutral-P1 inhibitors failed, highlighting Ala190

More Related Videos

PCR Mutagenesis, Cloning, Expression, Fast Protein Purification Protocols and Crystallization of the Wild Type and Mutant Forms of Tryptophan Synthase
09:31

PCR Mutagenesis, Cloning, Expression, Fast Protein Purification Protocols and Crystallization of the Wild Type and Mutant Forms of Tryptophan Synthase

Published on: September 26, 2020

Related Experiment Videos

Last Updated: May 23, 2026

Chemical Modification of the Tryptophan Residue in a Recombinant Ca2+-ATPase N-domain for Studying Tryptophan-ANS FRET
12:07

Chemical Modification of the Tryptophan Residue in a Recombinant Ca2+-ATPase N-domain for Studying Tryptophan-ANS FRET

Published on: October 9, 2021

PCR Mutagenesis, Cloning, Expression, Fast Protein Purification Protocols and Crystallization of the Wild Type and Mutant Forms of Tryptophan Synthase
09:31

PCR Mutagenesis, Cloning, Expression, Fast Protein Purification Protocols and Crystallization of the Wild Type and Mutant Forms of Tryptophan Synthase

Published on: September 26, 2020

Area of Science:

  • Biochemistry and enzymology
  • Drug discovery and medicinal chemistry

Background:

  • Beta-tryptase possesses a tetrameric structure with pairwise substrate binding sites.
  • This unique architecture presents an opportunity for designing inhibitors that target adjacent binding sites.
  • Previous success involved dimeric inhibitors with basic P1 moieties exhibiting tight-binding properties.

Purpose of the Study:

  • To design and synthesize dimeric inhibitors with neutral P1 groups.
  • To leverage the dimeric binding mode for beta-tryptase inhibitor optimization.
  • To investigate the feasibility of developing neutral-P1 inhibitors for beta-tryptase.

Main Methods:

  • Structure-based inhibitor design targeting beta-tryptase.
  • Synthesis of novel dimeric compounds with neutral P1 moieties.
  • Evaluation of inhibitor binding characteristics and efficacy.

Main Results:

  • The attempt to create dimeric inhibitors with neutral P1 groups was unsuccessful.
  • The study identified a crucial role for Alanine 190 (Ala190) in the binding of neutral P1 groups.
  • These findings cast doubt on the viability of developing neutral-P1 inhibitors for beta-tryptase using this strategy.

Conclusions:

  • The dimeric binding mode is less effective for neutral P1 inhibitors compared to basic P1 inhibitors.
  • Alanine 190 is a key residue influencing the binding of neutral P1 moieties in beta-tryptase.
  • Further research is needed to explore alternative strategies for developing neutral-P1 beta-tryptase inhibitors.